Hereditary genetic testing market seen reaching $40.12 billion by 2030

The Business Research Company says the hereditary genetic testing market will grow from $23.88 billion in 2025 to $26.56 billion in 2026, with demand driven by rising cancer prevalence, broader molecular diagnostics use and more genetic counseling. North America led the market in 2025 and is expected to stay the fastest-growing region through 2030.

Why it matters: - Hereditary genetic testing is becoming more important for early disease detection, cancer risk screening and personalized healthcare. - The market's growth reflects wider clinical use of genetic tools and rising awareness of inherited disease risk. - The report points to expanding demand for preventive and predictive testing across cancer, cardiovascular disease, rare disorders and prenatal and newborn screening.

What happened: - The Business Research Company released a hereditary genetic testing market intelligence report covering trends, segments and regional growth. - The report sizes the market at $23.88 billion in 2025 and projects $26.56 billion in 2026. - The report forecasts the market will reach $40.12 billion by 2030. - The report includes a free sample and the full market report.

The details: - The market is expected to grow at an 11.2% CAGR from 2025 to 2026. - The report projects a 10.9% CAGR through 2030. - Growth drivers include higher incidence of hereditary disorders, broader clinical use of molecular diagnostics, more diagnostic labs, stronger awareness of genetic diseases and wider access to basic genetic testing technologies. - Longer-term growth is tied to next-generation sequencing, personalized medicine, pharmacogenomics, preventive care investment and wider use of genetic counseling. - Key trends include more preventive and predictive genetic testing, higher demand for early cancer risk screening, direct-to-consumer testing, greater prenatal and newborn screening, and more awareness of inherited cardiovascular and rare diseases. - Hereditary genetic testing analyzes DNA to detect inherited mutations that can raise disease risk. - The testing is used to assess the chance of passing genetic conditions from parents to offspring. - The testing is commonly used to identify susceptibility to cancer, heart conditions and rare inherited disorders.

Between the lines: - Rising cancer prevalence is one of the clearest growth catalysts because genetic testing can help identify elevated risk before disease develops. - Macmillan Cancer Support reported in August 2024 that more than 3 million people in the UK were living with cancer in 2024, and that figure is expected to rise to 3.5 million by 2025, 4 million by 2030 and 5.3 million by 2040. - The report suggests the market is shifting from specialized testing toward broader preventive use as consumers and providers seek earlier, more targeted interventions. - North America held the largest market share in 2025 and is expected to remain the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The report says future growth will likely come from more adoption of sequencing-based tests, greater use of counseling and continued expansion of preventive screening. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The Business Research Company provided contact details for expert inquiries and report access, including email and regional phone numbers.

The bottom line: - Hereditary genetic testing is moving from a niche diagnostic category toward a larger preventive-health market, with cancer risk management and North American demand leading the next phase of growth.